You are viewing the site in preview mode

Skip to main content

Table 1 Study demographics. Data are from patients undergoing staging for newly diagnosed disease in whom a pathology reference was applied

From: PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review

RefAuthorYearCountryTracerScannerStudy designRecruitmentPatients, numbersRisk group distributionMean number of LN removed per patient
1Budaus et al. [16]2016GermanyGa-68-PSMA-11PET/CTRetroNon-con30High (100%)20
2Herlemann et al. [17]2016GermanyGa-68-PSMA-11PET/CTRetroCon20Int (20%), High (80%)14
3Maurer et al. [18]2016GermanyGa-68-PSMA-11PET/MR (73%), PET/CT (27%)RetroCon130Int (32%), High (68%)21a
4Van Leeuwen et al. [19]2017AustraliaGa-68-PSMA-11PET/CTProNon-con30Int (10%), High (90%)18
5Uprimny et al. [20]2017AustriaGa-68-PSMA-11PET/CTRetroNon-con49NRNR
6Gupta et al. [21]2017IndiaGa-68-PSMA-11PET/CTRetroNon-con12High (100%)20
7Obek et al. [22]2017TurkeyGa-68-PSMA-11PET/CTRetroNon-con51High (100%)20
8Zhang et al. [23]2017ChinaGa-68-PSMA-11PET/CTRetroCon42NR15
9Park et al. [24]2018USAGa-68-PSMA-11PET/MRProNon-con33High (45%), Int (55%)12
10Van Leeuwen et al. [25]2018The NetherlandsGa-68-PSMA-11PET/CTRetroCon140Int (21%), High (79%)NR
11Gorin et al. [26]2018USAF-18-DCFPyLPET/CTProNon-con25High (100%)13
12Cantiello et al. [27]2018ItalyCu-64-PSMAPET/CTProNon-con23Int (83), High (17)18
13Thalgott et al. [28]2018GermanyGa-68-PSMA-11PET/MRRetroCon73High (100%)26
14Berger et al. [29]2018AustraliaGa-68-PSMA-11PET/CTRetroNon-con50NR (pT3, 54%; Gleason ≥8; 32%)12a
15Gupta et al. [30]2018IndiaGa-68-PSMA-11PET/CTRetroCon23NR (83% High based on PSA and T-stage)20
16Yaxley et al. [31]2019AustraliaGa-68-PSMA-11PET/CTRetroCon208High (59%), Int (41%(14
17Yilmaz et al. [32]2019TurkeyGa-68-PSMA-11PET/CTRetroCon10NRNR
18Petersen et al. [33]2019DenmarkGa-68-PSMA-11PET/MR (85%), PET/CT (15%)ProCon20High (95%), Int (5%)29
  1. aMedian
  2. Abbreviations. Con consecutive, Int intermediate, LN lymph node, Non-con non-consecutive, NR not reported, Pro prospective, Retro retrospective
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us